| Whole genome sequencing of multiple Leishmania donovani clinical isolates provides insights into population structure and mechanisms of drug resistance T Downing, H Imamura, S Decuypere, TG Clark, GH Coombs, JA Cotton, ... Genome research 21 (12), 2143-2156, 2011 | 483 | 2011 |
| Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance S Rijal, B Ostyn, S Uranw, K Rai, NR Bhattarai, TPC Dorlo, JH Beijnen, ... Clinical Infectious Diseases 56 (11), 1530-1538, 2013 | 353 | 2013 |
| Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics AN Cowell, ES Istvan, AK Lukens, MG Gomez-Lorenzo, M Vanaerschot, ... Science 359 (6372), 191-199, 2018 | 216 | 2018 |
| Evolutionary genomics of epidemic visceral leishmaniasis in the Indian subcontinent H Imamura, T Downing, F Van den Broeck, MJ Sanders, S Rijal, S Sundar, ... Elife 5, e12613, 2016 | 161 | 2016 |
| Modulation of Aneuploidy in Leishmania donovani during Adaptation to Different In Vitro and In Vivo Environments and Its Impact on Gene Expression F Dumetz, H Imamura, M Sanders, V Seblova, J Myskova, P Pescher, ... MBio 8 (3), 10.1128/mbio. 00599-17, 2017 | 150 | 2017 |
| Evaluation of normalization methods to pave the way towards large-scale LC-MS-based metabolomics profiling experiments BA Ejigu, D Valkenborg, G Baggerman, M Vanaerschot, E Witters, ... Omics: a journal of integrative biology 17 (9), 473-485, 2013 | 121 | 2013 |
| Open-source discovery of chemical leads for next-generation chemoprotective antimalarials Y Antonova-Koch, S Meister, M Abraham, MR Luth, S Ottilie, AK Lukens, ... Science 362 (6419), eaat9446, 2018 | 110 | 2018 |
| Molecular Mechanisms of Drug Resistance in Natural Leishmania Populations Vary with Genetic Background S Decuypere, M Vanaerschot, K Brunker, H Imamura, S Müller, B Khanal, ... PLoS neglected tropical diseases 6 (2), e1514, 2012 | 100 | 2012 |
| Treatment failure in leishmaniasis: drug-resistance or another (epi-) phenotype? M Vanaerschot, F Dumetz, S Roy, A Ponte-Sucre, J Arevalo, JC Dujardin Expert review of anti-infective therapy 12 (8), 937-946, 2014 | 87 | 2014 |
| Antileishmanial Activity of a Series of N2,N4-Disubstituted Quinazoline-2,4-diamines KS Van Horn, X Zhu, T Pandharkar, S Yang, B Vesely, M Vanaerschot, ... Journal of medicinal chemistry 57 (12), 5141-5156, 2014 | 82 | 2014 |
| Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain K Rai, B Cuypers, NR Bhattarai, S Uranw, M Berg, B Ostyn, JC Dujardin, ... MBio 4 (5), 10.1128/mbio. 00611-13, 2013 | 82 | 2013 |
| Linking in vitro and in vivo survival of clinical Leishmania donovani strains M Vanaerschot, I Maes, M Ouakad, V Adaui, L Maes, S De Doncker, ... PLoS One 5 (8), e12211, 2010 | 78 | 2010 |
| Detection of Leptomonas sp. parasites in clinical isolates of Kala-azar patients from India P Srivastava, VK Prajapati, M Vanaerschot, G Van der Auwera, ... Infection, Genetics and Evolution 10 (7), 1145-1150, 2010 | 71 | 2010 |
| Identification of a polymorphism in the N gene of SARS-CoV-2 that adversely impacts detection by reverse transcription-PCR M Vanaerschot, SA Mann, JT Webber, J Kamm, SM Bell, J Bell, SN Hong, ... Journal of Clinical Microbiology 59 (1), 10.1128/jcm. 02369-20, 2020 | 68 | 2020 |
| Drug resistance in vectorborne parasites: multiple actors and scenarios for an evolutionary arms race M Vanaerschot, S Huijben, F Van den Broeck, JC Dujardin FEMS microbiology reviews 38 (1), 41-55, 2014 | 64 | 2014 |
| LC-MS metabolomics from study design to data-analysis–using a versatile pathogen as a test case M Berg, M Vanaerschot, A Jankevics, B Cuypers, R Breitling, JC Dujardin Computational and structural biotechnology journal 4 (5), e201301002, 2013 | 64 | 2013 |
| Combining stage specificity and metabolomic profiling to advance antimalarial drug discovery JM Murithi, ES Owen, ES Istvan, MCS Lee, S Ottilie, K Chibale, ... Cell chemical biology 27 (2), 158-171. e3, 2020 | 63 | 2020 |
| Metabolic adaptations of Leishmania donovani in relation to differentiation, drug resistance, and drug pressure M Berg, M Vanaerschot, A Jankevics, B Cuypers, I Maes, S Mukherjee, ... Molecular microbiology 90 (2), 428-442, 2013 | 63 | 2013 |
| Treatment of Visceral Leishmaniasis: Model-Based Analyses on the Spread of Antimony-Resistant L. donovani in Bihar, India A Stauch, HP Duerr, JC Dujardin, M Vanaerschot, S Sundar, M Eichner PLoS neglected tropical diseases 6 (12), e1973, 2012 | 63 | 2012 |
| Genome-wide SNP and microsatellite variation illuminate population-level epidemiology in the Leishmania donovani species complex T Downing, O Stark, M Vanaerschot, H Imamura, M Sanders, ... Infection, Genetics and Evolution 12 (1), 149-159, 2012 | 63 | 2012 |
